Enterprise Value
75.91B
Cash
8.928B
Avg Qtr Burn
N/A
Short % of Float
1.35%
Insider Ownership
2.54%
Institutional Own.
89.45%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Evkeeza (evinacumab) Details Homozygous familial hypercholesterolemia | Approved Update | |
EYLEA (aflibercept) Details Retinopathy of prematurity | Approved Quarterly sales | |
EYLEA (aflibercept) Details Diabetic retinopathy | Approved Quarterly sales | |
EYLEA HD (aflibercept) Details Wet age-related macular degeneration , Diabetic macular edema | Approved Quarterly sales | |
Libtayo® (cemiplimab) Details Non-small cell lung carcinoma, Cutaneous squamous cell carcinoma | Approved Quarterly sales | |
Kevzara (sarilumab) Details Polymyalgia rheumatica | Approved Quarterly sales | |
Veopoz™ (pozelimab-bbfg) Details Rare diseases, CD55-deficient protein-losing enteropathy , CHAPLE disease | Approved Quarterly sales | |
Odronextamab Details Follicular lymphoma, Diffuse large B cell lymphoma | PDUFA Approval decision | |
Dupixent® (dupilumab) (IL-4 IL-13) Details Eosinophilic Esophagitis | PDUFA Approval decision | |
Dupixent Details Chronic obstructive pulmonary disease | BLA Submission | |
Dupixent (dupilumab) Details Skin disease/disorder, Atopic dermatitis | Phase 3 Data readout | |
Itepekimab Details Chronic obstructive pulmonary disease | Phase 3 Data readout | |
Dupixent® (dupilumab) (IL-4 IL-13) Details Chronic spontaneous urticaria | Phase 3 Data readout | |
Fianlimab + Libtayo® (cemiplimab) Details Melanoma, Advanced malignancies | Phase 3 Update | |
Linvoseltamab(BCMAXCD3) Details Blood cancer, Cancer, Multiple myeloma | Phase 2 Data readout | |
Dupixent Details Chronic inducible urticaria | Failed Discontinued |